<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab1">
 <label>Table 1</label>
 <caption>
  <p>Main Inclusion and Exclusion Criteria</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th colspan="2">Inclusion Criteria</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td colspan="2">1) Patients providing the written informed consent</td>
   </tr>
   <tr>
    <td colspan="2">2) Patients with non-small-cell lung cancer histopathologically confirmed</td>
   </tr>
   <tr>
    <td colspan="2">3) Patients with total resection in pathological clinical stage II - IIIA with more than one lobe excision was carried out</td>
   </tr>
   <tr>
    <td colspan="2">4) Patients with lymphadenectomy more than ND2a-1 or selective lymphadenectomy</td>
   </tr>
   <tr>
    <td colspan="2"> The selection method of the mediastinal lymph node dissected obeys the following criteria</td>
   </tr>
   <tr>
    <td colspan="2">●Right upper lobe lung cancer (LC); No.2R,4R</td>
   </tr>
   <tr>
    <td colspan="2">●Left upper lobe segmentum superius LC; No. 4 L-6</td>
   </tr>
   <tr>
    <td>●Right middle lobe LC;</td>
    <td>No.2R,4R,7</td>
   </tr>
   <tr>
    <td colspan="2">●Left upper lobe lingual LC; No.4 L-7</td>
   </tr>
   <tr>
    <td colspan="2">●Right lower lobe LC; No.7–9</td>
   </tr>
   <tr>
    <td colspan="2">●Left lower lobe LC; No.7–9</td>
   </tr>
   <tr>
    <td colspan="2">5) Patients without pre-treatment (radiation, chemotherapy) other than surgical treatment</td>
   </tr>
   <tr>
    <td colspan="2">6) Patients who passed more than 28 days and less than 56 days after the operation at enrollment</td>
   </tr>
   <tr>
    <td colspan="2">7) Patient is at least 20 years and less than 75 years of age (at enrollment date).</td>
   </tr>
   <tr>
    <td colspan="2">8) Patients capable of treatment with oral medicine.</td>
   </tr>
   <tr>
    <td colspan="2">9) Eastern Cooperative Oncology Group (ECOG) performance status of 0–1</td>
   </tr>
   <tr>
    <td colspan="2">10) Patients having sufficient bone marrow, liver and renal function tolerable to chemotherapy</td>
   </tr>
   <tr>
    <td colspan="2">Exclusion Criteria</td>
   </tr>
   <tr>
    <td colspan="2">1) Patients with active double cancer (synchronous double cancer and asynchronous double cancer within 5 years of progression-free  period)</td>
   </tr>
   <tr>
    <td colspan="2">2) Patients with anamnesis of drug-induced hypersensitivity.</td>
   </tr>
   <tr>
    <td colspan="2">3) Patients with severe postoperative complications (such as postoperative infection, rapture suture).</td>
   </tr>
   <tr>
    <td colspan="2">4) Patients with severe complications (such as diarrhoea, intestinal paralysis, ileus, uncontrollable diabetes mellitus, heart failure, kidney failure, liver failure).</td>
   </tr>
   <tr>
    <td colspan="2">5) Patients with interstitial pattern recognized as apparent interstitial pneumonia in chest CT.</td>
   </tr>
   <tr>
    <td colspan="2">6) Patients with active infection.</td>
   </tr>
   <tr>
    <td colspan="2">7) Female patients pregnant or possibly pregnant (will), or nursing.</td>
   </tr>
   <tr>
    <td colspan="2">8) Patients under treatment with a type of fluorinated pyrimidine antineoplastic.</td>
   </tr>
   <tr>
    <td colspan="2">9) Patients under treatment of flucytosine.</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
